Bristol Myers Squibb, bluebird land once-high-stakes approval on BCMA CAR-T — and it bodes well for rival J&J

Amber Tong

Almost a year after getting slammed by a surprise refuse-to-file letter, Bristol Myers Squibb and bluebird have been cleared to market the first BCMA CAR …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers Squibb, bluebird land once-high-stakes approval on BCMA CAR-T — and it bodes well for rival J&J

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Bris­tol My­ers Squibb, blue­bird land once-high-stakes ap­proval on BC­MA CAR-T — and it bodes well for ri­val J&J

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers Squibb, bluebird land once-high-stakes approval on BCMA CAR-T — and it bodes well for rival J&J